Lawrence Howard Schwartz
#119,292
Most Influential Person Now
Lawrence Howard Schwartz's AcademicInfluence.com Rankings
Lawrence Howard Schwartzphilosophy Degrees
Philosophy
#5338
World Rank
#8106
Historical Rank
Logic
#2632
World Rank
#3648
Historical Rank

Download Badge
Philosophy
Lawrence Howard Schwartz's Degrees
- Doctorate Medicine University of California, San Francisco
Why Is Lawrence Howard Schwartz Influential?
(Suggest an Edit or Addition)Lawrence Howard Schwartz's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (2009) (17488)
- The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS) (2015) (3526)
- Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (2014) (3134)
- The Lung Image Database Consortium (LIDC) and Image Database Resource Initiative (IDRI): a completed reference database of lung nodules on CT scans. (2011) (1735)
- Artificial intelligence in radiology (2018) (1426)
- Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. (2007) (1335)
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. (2017) (1304)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (2006) (1169)
- Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. (2014) (1153)
- Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. (2005) (1127)
- RECIST 1.1-Update and clarification: From the RECIST committee. (2016) (944)
- Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. (2005) (898)
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) (889)
- Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. (2004) (741)
- Intrahepatic Cholangiocarcinoma: Rising Frequency, Improved Survival, and Determinants of Outcome After Resection (2008) (690)
- Artificial intelligence in cancer imaging: Clinical challenges and applications (2019) (689)
- Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003) (662)
- Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007) (632)
- Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. (2009) (510)
- Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection (2003) (462)
- Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. (2010) (413)
- Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. (2006) (411)
- Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. (2006) (405)
- Reproducibility of radiomics for deciphering tumor phenotype with imaging (2016) (387)
- Improving communication of diagnostic radiology findings through structured reporting. (2011) (385)
- Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. (2010) (378)
- Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. (2016) (353)
- Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. (2009) (304)
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. (2016) (303)
- Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus (2007) (297)
- NCCN clinical practice guidelines in oncology: kidney cancer. (2009) (286)
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer (2007) (274)
- Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study. (2006) (264)
- Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. (2016) (260)
- Prevalence and importance of small hepatic lesions found at CT in patients with cancer. (1999) (254)
- Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. (2000) (250)
- Evaluation of lymph nodes with RECIST 1.1. (2009) (235)
- Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. (2005) (228)
- Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. (2010) (227)
- Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. (1998) (215)
- Sorafenib for Advanced and Refractory Desmoid Tumors (2018) (214)
- Renal masses: characterization with diffusion-weighted MR imaging--a preliminary experience. (2008) (212)
- Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. (2005) (208)
- MR imaging of the breast in patients with occult primary breast carcinoma. (1997) (208)
- International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) (2017) (207)
- Test–Retest Reproducibility Analysis of Lung CT Image Features (2014) (205)
- Diagnosis, management, and outcomes of 115 patients with hepatic hemangioma. (2003) (204)
- Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. (2009) (200)
- Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 (2015) (199)
- Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. (2002) (198)
- Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. (1997) (194)
- Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. (2005) (191)
- Automatic detection of small lung nodules on CT utilizing a local density maximum algorithm (2003) (189)
- Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trials (2018) (183)
- Phase II trial of bortezomib for patients with advanced renal cell carcinoma. (2004) (180)
- Individual patient data analysis to assess modifications to the RECIST criteria. (2009) (180)
- Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. (2001) (176)
- Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases (2008) (175)
- NCCN clinical practice guidelines in oncology: testicular cancer. (2009) (173)
- RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. (2016) (172)
- CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. (2011) (171)
- Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society (2004) (169)
- Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC (2016) (169)
- Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas (2017) (169)
- Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. (1994) (166)
- Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. (2007) (160)
- Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes. (2013) (157)
- Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. (1995) (155)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC) (2018) (154)
- 32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1 (2008) (150)
- Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. (2004) (148)
- Liver segmentation for CT images using GVF snake. (2005) (147)
- A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma (2006) (147)
- Pulmonary nodules resected at video-assisted thoracoscopic surgery: etiology in 426 patients. (1999) (141)
- Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. (2009) (140)
- Quantitative imaging biomarkers: A review of statistical methods for computer algorithm comparisons (2014) (139)
- Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards (2005) (136)
- Dynamic contrast enhanced-MRI for the detection of pathological complete response to neoadjuvant chemotherapy for locally advanced rectal cancer (2012) (132)
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. (2012) (130)
- Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy (2005) (123)
- Osteogenic and Ewing sarcomas: estimation of necrotic fraction during induction chemotherapy with dynamic contrast-enhanced MR imaging. (2003) (122)
- Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acid. (2006) (119)
- Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer (2005) (118)
- Lung cancer: computerized quantification of tumor response--initial results. (2006) (118)
- Validation of novel imaging methodologies for use as cancer clinical trial end-points. (2009) (117)
- When progressive disease does not mean treatment failure: reconsidering the criteria for progression. (2012) (117)
- Endometrial stromal sarcoma: objective response to letrozole. (2001) (117)
- Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). (2016) (113)
- Recommendations for the assessment of progression in randomised cancer treatment trials. (2009) (111)
- Assessing Agreement between Radiomic Features Computed for Multiple CT Imaging Settings (2016) (111)
- Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. (2001) (110)
- A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development (2010) (109)
- Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer (2018) (109)
- Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. (1999) (106)
- Exploring Variability in CT Characterization of Tumors: A Preliminary Phantom Study. (2014) (102)
- Lessons learned from independent central review. (2009) (101)
- Segmentation of lung lesions on CT scans using watershed, active contours, and Markov random field. (2013) (101)
- Evaluation of tumor measurements in oncology: use of film-based and electronic techniques. (2000) (100)
- 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. (2006) (98)
- Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. (2006) (97)
- Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. (2000) (97)
- Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. (1999) (96)
- Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. (2012) (95)
- Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. (2010) (91)
- A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. (2018) (91)
- Radiomics machine-learning signature for diagnosis of hepatocellular carcinoma in cirrhotic patients with indeterminate liver nodules (2019) (90)
- Quantitative Imaging in Cancer Clinical Trials (2016) (90)
- Neoplastic pancreaticobiliary duct obstruction: evaluation with breath-hold MR cholangiopancreatography. (1998) (89)
- Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. (2009) (89)
- Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers* (2009) (88)
- Quantitative imaging test approval and biomarker qualification: interrelated but distinct activities. (2011) (88)
- A statistical simulation study finds discordance between WHO criteria and RECIST guideline. (2004) (88)
- Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. (2012) (87)
- 18F-FDG PET and CT Scans Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti–Programmed Death 1 Immune Checkpoint Inhibitor (2018) (86)
- Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results (2011) (86)
- Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. (2021) (86)
- Hepatocellular carcinoma: MR imaging findings in cirrhotic livers and noncirrhotic livers. (1999) (85)
- Preoperative radiographic assessment of hepatic steatosis with histologic correlation. (2008) (85)
- Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors (2009) (84)
- Gemcitabine‐related radiation recall preferentially involves internal tissue and organs (2004) (84)
- Promise and pitfalls of quantitative imaging in oncology clinical trials. (2012) (83)
- Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. (2009) (83)
- Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy (2008) (83)
- Sarcomatoid-variant Renal Cell Carcinoma: Treatment Outcome and Survival in Advanced Disease (2011) (81)
- Gallbladder Carcinoma: Findings at MR Imaging With MR Cholangiopancreatography (2002) (81)
- Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. (2003) (80)
- Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab (2017) (80)
- Collision tumors of the adrenal gland: demonstration and characterization at MR imaging. (1996) (79)
- BRENTUXIMAB VEDOTIN AND BENDAMUSTINE (BvB) IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: AN INTERNATIONAL, MULTICENTER, SINGLE-ARM, PHASE 1–2 TRIAL (2017) (78)
- Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans (2010) (77)
- Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics (2019) (76)
- Phase II Trial of Arsenic Trioxide in Patients with Metastatic Renal Cell Carcinoma (2002) (76)
- Marker-controlled watershed for lymphoma segmentation in sequential CT images. (2006) (76)
- Radiomics Response Signature for Identification of Metastatic Colorectal Cancer Sensitive to Therapies Targeting EGFR Pathway. (2020) (75)
- Automated Quantification of Body Fat Distribution on Volumetric Computed Tomography (2006) (73)
- The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas (2006) (73)
- Exploring intra- and inter-reader variability in uni-dimensional, bi-dimensional, and volumetric measurements of solid tumors on CT scans reconstructed at different slice intervals. (2013) (72)
- Radiation therapy in the treatment of difficult giant cell tumors. (1989) (72)
- Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response (2011) (72)
- Update on colorectal cancer imaging. (2012) (71)
- Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors (2007) (70)
- Prospective comparison of T2-weighted fast spin-echo, with and without fat suppression, and conventional spin-echo pulse sequences in the upper abdomen. (1993) (67)
- Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. (2019) (67)
- Lymph node segmentation from CT images using fast marching method. (2004) (67)
- Feasibility of using limited‐population‐based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast‐enhanced MRI data (2008) (66)
- Adrenal masses in patients with malignancy: prospective comparison of echo-planar, fast spin-echo, and chemical shift MR imaging. (1995) (66)
- Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. (2003) (66)
- Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics (2020) (65)
- Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. (2008) (64)
- Ki-67 is a Prognostic Biomarker of Survival after Radiofrequency Ablation of Liver Malignancies (2012) (63)
- Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. (2011) (61)
- Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. (2009) (60)
- Hybrid detection of lung nodules on CT scan images. (2015) (59)
- Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results (2011) (58)
- Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors (2015) (57)
- Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. (2011) (56)
- Imaging response assessment in oncology (2006) (55)
- Comparison of magnetic resonance and endoscopic retrograde cholangiopancreatography in malignant pancreaticobiliary obstruction. (1999) (55)
- Pulmonary metastases: effect of CT section thickness on measurement--initial experience. (2005) (54)
- Intraoperative conformal optimization for transperineal prostate implantation using magnetic resonance spectroscopic imaging. (2000) (53)
- A simulation study to evaluate the impact of the number of lesions measured on response assessment. (2009) (53)
- CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study (2018) (53)
- Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. (2005) (53)
- Characterization of Pneumonitis in Patients with Advanced Non-small Cell Lung Cancer Treated with Everolimus (RAD001) (2009) (52)
- The use of volumetric CT as an imaging biomarker in lung cancer. (2010) (51)
- Early invasive cervical cancer: MRI and CT predictors of lymphatic metastases in the ACRIN 6651/GOG 183 intergroup study. (2009) (50)
- Prognostic Value of Interim FDG-PET in Diffuse Large Cell Lymphoma: Results from the CALGB 50303 Clinical Trial. (2020) (50)
- Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standard of reference than spleen? (1997) (50)
- Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population (2010) (49)
- Malignant lesion segmentation in contrast-enhanced breast MR images based on the marker-controlled watershed. (2009) (48)
- Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer (2008) (48)
- Misrepresentation of publications by applicants for radiology fellowships: is it a problem? (1997) (48)
- Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. (2010) (47)
- Retained seminal vesicles after radical prostatectomy: frequency, MRI characteristics, and clinical relevance. (2006) (47)
- Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study (2020) (47)
- Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. (2010) (47)
- Correlation between tumor measurement on Computed Tomography and resected specimen size in lung adenocarcinomas. (2012) (46)
- Bicalutamide for Advanced Prostate Cancer: The Natural Versus Treated History of Disease (1998) (46)
- Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation (2011) (45)
- Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies (2004) (45)
- Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? (2012) (44)
- Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography (2019) (44)
- Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4 (2020) (44)
- Hepatic intraductal oncocytic papillary carcinoma (2002) (43)
- Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival (2010) (43)
- Recognition of Intrabiliary Hepatic Metastases From Colorectal Adenocarcinoma (2000) (42)
- How to assess anti-tumour efficacy by imaging techniques. (2008) (42)
- The use of imaging in the diagnosis and staging of hepatobiliary malignancies. (2007) (42)
- Radiomics for Classification of Lung Cancer Histological Subtypes Based on Nonenhanced Computed Tomography. (2019) (42)
- Fully Automatic Brain Tumor Segmentation from Multiple MR Sequences using Hidden Markov Fields and Variational (2013) (42)
- Shape-Constraint Region Growing for Delineation of Hepatic Metastases on Contrast-Enhanced Computed Tomograph Scans (2006) (41)
- Hepatic arterial infusion of floxuridine and dexamethasone plus high‐dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma (2005) (41)
- Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment. (1998) (41)
- Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy (2008) (41)
- Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. (2020) (40)
- Automatic Liver Segmentation by Integrating Fully Convolutional Networks into Active Contour Models. (2019) (39)
- Bone marrow segmentation in leukemia using diffusion and T 2 weighted echo planar magnetic resonance imaging (2000) (39)
- RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. (2019) (39)
- High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy (2016) (38)
- Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging (2017) (38)
- Complex postcholecystectomy biliary disorders: preliminary experience with evaluation by means of breath-hold MR cholangiography. (1998) (38)
- Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials (2003) (37)
- Imaging of hepatocellular carcinoma: a practical approach. (2001) (37)
- High‐dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma (2004) (37)
- Recurrent gallbladder carcinoma along laparoscopic cholecystectomy port tracks: CT demonstration. (1999) (36)
- Eye Tracking for Deep Learning Segmentation Using Convolutional Neural Networks (2019) (36)
- An Automatic Method for Ground Glass Opacity Nodule Detection and Segmentation from CT Studies (2006) (35)
- Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma (2003) (35)
- MRI as an alternative to CT-guided biopsy of adrenal masses in patients with lung cancer. (1998) (35)
- Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial. (2013) (35)
- Incremental value of multiplanar cross-referencing for prostate cancer staging with endorectal MRI. (2007) (35)
- Multiphasic contrast‐enhanced MRI: Single‐slice versus volumetric quantification of tumor enhancement for the assessment of renal clear‐cell carcinoma fuhrman grade (2013) (35)
- Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. (2006) (34)
- Semiautomatic segmentation of liver metastases on volumetric CT images. (2015) (33)
- iRECIST: how to do it (2020) (33)
- Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials (2014) (33)
- A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors (2012) (32)
- Kinetics of liver volume changes in the first year after portal vein embolization. (2010) (32)
- Interobserver variability in tumor contouring affects the use of radiomics to predict mutational status (2017) (31)
- Non-neoplastic causes of high signal intensity at T2-weighted MR imaging after treatment for musculoskeletal neoplasm (1995) (30)
- Response Rate as a Regulatory End Point in Single-Arm Studies of Advanced Solid Tumors. (2016) (30)
- Quantitative Volumetric CT-Histogram Analysis in N-Staging of 18F-FDG–Equivocal Patients with Lung Cancer (2014) (30)
- Small cell and anaplastic prostate cancer: correlation between CT findings and prostate-specific antigen level. (1998) (30)
- The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). (2015) (30)
- Preliminary assessment of magnetic resonance spectroscopic imaging in predicting treatment outcome in patients with prostate cancer at high risk for relapse. (2004) (29)
- Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review. (2021) (29)
- Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer (2021) (29)
- Automatic Detection and Segmentation of Ground Glass Opacity Nodules (2006) (28)
- Application of Radiomics in Predicting the Malignancy of Pulmonary Nodules in Different Sizes. (2019) (28)
- Voice recognition in radiology reporting. (1997) (28)
- Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202). (2019) (28)
- Early 18F-FDG PET/CT Response Predicts Survival in Relapsed or Refractory Hodgkin Lymphoma Treated with Nivolumab (2019) (28)
- Case report. Adrenocortical oncocytoma: CT and MRI findings. (1996) (27)
- Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. (2018) (27)
- Determining the Variability of Lesion Size Measurements from CT Patient Data Sets Acquired under “No Change” Conditions12 (2015) (27)
- The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective. (2018) (27)
- Radiomic Analysis using Density Threshold for FDG-PET/CT-Based N-Staging in Lung Cancer Patients (2017) (27)
- Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. (2015) (26)
- Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma (2008) (26)
- Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma. (2020) (25)
- A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). (2020) (25)
- Phase II Trial of Irofulven (6-Hydroxymethylacylfulvene) for Patients with Advanced Renal Cell Carcinoma (2004) (25)
- Gemcitabine-induced pulmonary toxicity. (2012) (25)
- Non-Hodgkin lymphoma in skeletal muscle manifesting as homogeneous masses with CT attenuation similar to muscle (1997) (25)
- Paclitaxel in germ cell cancer. (1995) (25)
- Toward Generalizability in the Deployment of Artificial Intelligence in Radiology: Role of Computation Stress Testing to Overcome Underspecification (2021) (24)
- Breath‐Hold Magnetic Resonance Cholangiopancreatography in the Evaluation of Malignant Pancreaticobiliary Obstruction (2003) (24)
- Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST (2020) (24)
- Future vision for the quality assurance of oncology clinical trials (2013) (24)
- Breast cancer: assessing the use of routine pelvic CT in patient evaluation. (2001) (24)
- Medical Imaging in Clinical Trials (2014) (24)
- CT-Based Radiomics Model for Predicting Brain Metastasis in Category T1 Lung Adenocarcinoma. (2019) (22)
- Reliability of Radiomic Features Across Multiple Abdominal CT Image Acquisition Settings: A Pilot Study Using ACR CT Phantom (2019) (22)
- Assessing the effect of CT slice interval on unidimensional, bidimensional and volumetric measurements of solid tumours (2012) (22)
- Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor (2016) (22)
- A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (2005) (22)
- MR imaging of carcinoma within urinary bladder diverticulum. (1997) (22)
- Comparison of two algorithms and their associated charges when evaluating adrenal masses in patients with malignancies. (1997) (22)
- Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence (2019) (21)
- Radiomics Prediction of EGFR Status in Lung Cancer—Our Experience in Using Multiple Feature Extractors and The Cancer Imaging Archive Data (2020) (21)
- A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma (2004) (20)
- Magnetic resonance cholangiopancreatography (1999) (20)
- Preoperative modified FOLFIRINOX (mFOLFIRINOX) followed by chemoradiation (CRT) for borderline resectable (BLR) pancreatic cancer (PDAC): Initial results from Alliance Trial A021101. (2015) (20)
- Non-Hodgkin lymphoma as a cause of intrahepatic periportal low attenuation on CT. (1997) (20)
- Data sets for the qualification of volumetric CT as a quantitative imaging biomarker in lung cancer. (2010) (20)
- Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) (2017) (19)
- Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm (2014) (19)
- Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma (2008) (19)
- Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis (2018) (19)
- Routine editing of trainee-generated radiology reports: effect on style quality. (2003) (18)
- Liver regeneration in humans is characterized by significant changes in cellular phosphorus metabolism: Assessment using proton‐decoupled 31P‐ magnetic resonance spectroscopic imaging (2005) (18)
- Prospective, Blinded Comparison of Helical CT and CT Arterial Portography in the Assessment of Hepatic Metastasis from Colorectal Carcinoma (2006) (18)
- Assessing outcomes in prostate cancer clinical trials (2008) (18)
- [Antioxidant minerals and vitamins. Role in cancer prevention]. (1994) (18)
- Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging (2021) (18)
- Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. (2017) (18)
- Primary Cutaneous Lymphoma: Recommendations for Clinical Trial Design and Staging Update from the ISCL, USCLC, and EORTC. (2021) (18)
- Contrast-enhanced ultrasound monitoring of perfusion changes in hepatic neuroendocrine metastases after systemic versus selective arterial 177Lu/90Y-DOTATOC and 213Bi-DOTATOC radiopeptide therapy. (2013) (18)
- Do Radiologists Have Stage Fright? Tumor Staging and How We Can Add Value to the Care of Patients with Cancer. (2016) (17)
- A theoretical approach to choosing the minimum number of multiple tumors required for assessing treatment response. (2005) (17)
- Application of the LDM algorithm to identify small lung nodules on low-dose MSCT scans (2004) (17)
- A Response Assessment Platform for Development and Validation of Imaging Biomarkers in Oncology (2016) (17)
- Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial. (2014) (17)
- Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. (2004) (17)
- Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma (2008) (17)
- Volumetric 3D CT analysis - an early predictor of response to therapy (2007) (17)
- Prognostic Aspects of DCE-MRI in Recurrent Rectal Cancer (2013) (16)
- Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases (2004) (16)
- Effects of superparamagnetic iron oxide (AMI-25) on liver and spleen imaging using spin-echo and fast spin-echo magnetic resonance pulse sequences. (1994) (16)
- Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients (2011) (16)
- Time to tumor growth: a model end point and new metric system for oncology clinical trials. (2013) (16)
- Letter to cancer center directors: Progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. (2014) (16)
- Feasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data. (2009) (16)
- Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy (2013) (16)
- Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors (2004) (16)
- Echoplanar MR imaging for characterization of adrenal masses in patients with malignant neoplasms: preliminary evaluation of calculated T2 relaxation values. (1995) (15)
- The Imaging Viewpoint: How Imaging Affects Determination of Progression-Free Survival (2013) (15)
- Shared Patient Analysis: A Method to Assess the Clinical Benefits of Patient Referrals (2001) (15)
- CT-guided automated detection of lung tumors on PET images (2008) (15)
- Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine. (2002) (15)
- Prediction of Lymph Node Maximum Standardized Uptake Value in Patients With Cancer Using a 3D Convolutional Neural Network: A Proof-of-Concept Study. (2019) (15)
- Imaging of neuroendocrine tumors. (2013) (15)
- Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. (2016) (14)
- Mesenteric adenopathy in patients with prostate cancer: frequency and etiology. (2002) (14)
- Implementation Strategy of a CNN Model Affects the Performance of CT Assessment of EGFR Mutation Status in Lung Cancer Patients (2019) (14)
- Repeatability of Quantitative Diffusion-Weighted Imaging Metrics in Phantoms, Head-and-Neck and Thyroid Cancers: Preliminary Findings (2019) (14)
- Vessel Size Imaging (VSI) by Robust Magnetic Resonance (MR) Relaxometry: MR-VSI of Solid Tumors in Correlation with Immunohistology and Intravital Microscopy (2013) (13)
- A Nonrandomized, Phase II Study of Sequential Irinotecan and Flavopiridol in Patients With Advanced Hepatocellular Carcinoma. (2012) (13)
- Contemporary imaging in sarcoma. (2009) (13)
- A randomized single blind controlled trial of beads versus doxorubicin-eluting beads for arterial embolization of hepatocellular carcinoma (HCC). (2013) (13)
- Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) (2021) (13)
- Differentiation of Focal-Type Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma Using Radiomics Based on Multiphasic Computed Tomography. (2020) (13)
- Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. (2003) (13)
- Comparison of phased-array and body coils for MR imaging of liver. (1997) (12)
- MR enteroclysis: evaluation of small-bowel obstruction in a patient with pseudomyxoma peritonei. (2000) (12)
- Patterns of neoplastic spread in colorectal cancer: implications for surveillance CT studies. (1998) (12)
- Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. (2020) (12)
- A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). (2019) (12)
- Metiv-HCC: A phase III clinical trial evaluating tivantinib (ARQ 197), a MET inhibitor, versus placebo as second-line in patients (pts) with MET-high inoperable hepatocellular carcinoma (HCC). (2013) (12)
- Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. (2018) (12)
- Automated matching and segmentation of lymphoma on serial CT examinations. (2006) (12)
- Doxorubicin, Vinblastine and Gemcitabine (AVG), a Novel Regimen Excluding Bleomycin for the Treatment of Early Stage Hodgkin Lymphoma (HL): Results of CALGB 50203. (2007) (11)
- PreoperativeModified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer Alliance for Clinical Trials in Oncology Trial A 021101 (2019) (11)
- Recurrence Patterns of Intraductal Papillary Mucinous Neoplasms of the Pancreas on Enhanced Computed Tomography (2009) (11)
- Automatic liver contour segmentation using GVF snake (2004) (11)
- Use of Imaging for GI Cancers. (2015) (10)
- Volumetry of low-contrast liver lesions with CT: Investigation of estimation uncertainties in a phantom study. (2016) (10)
- Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study (2018) (10)
- Using a single abdominal computed tomography image to differentiate five contrast-enhancement phases: A machine-learning algorithm for radiomics-based precision medicine. (2020) (10)
- Soft Tissue Edema Around Musculoskeletal Sarcomas at Magnetic Resonance Imaging (1997) (10)
- Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy (2004) (10)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma (2022) (10)
- Imaging approaches with advanced prostate cancer: techniques and timing. (2014) (10)
- CT bone window photography in patients with cancer. (1995) (10)
- Lymph node segmentation by dynamic programming and active contours. (2018) (10)
- Quantitative Imaging Metrics Derived from Magnetic Resonance Fingerprinting using ISMRM/NIST MRI System Phantom: An International Multi-Center Repeatability and Reproducibility Study. (2021) (10)
- Diagnosis of Hyperprogressive Disease in Patients Treated with Checkpoint Inhibitors Using 18F-FDG PET/CT (2020) (9)
- Quantitative X-ray Computed Tomography Peritoneography in Malignant Peritoneal Mesothelioma Patients Receiving Intraperitoneal Chemotherapy (2013) (9)
- A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma (2020) (9)
- Multicenter Repeatability Study of a Novel Quantitative Diffusion Kurtosis Imaging Phantom (2019) (9)
- CT in searching for abscess after abdominal or pelvic surgery in patients with neoplasia: do abdomen and pelvis both need to be scanned? (1997) (9)
- Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial (2020) (9)
- Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue. (2013) (9)
- OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer (2019) (9)
- MR Imaging of Bone Marrow in Patients with Musculoskeletal Tumors (1999) (8)
- Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2013) (8)
- Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies. (2017) (8)
- Uncontrolled Confounders May Lead to False or Overvalued Radiomics Signature: A Proof of Concept Using Survival Analysis in a Multicenter Cohort of Kidney Cancer (2021) (8)
- Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients (2021) (8)
- Assessment of Neurovascular Involvement by Malignant Musculoskeletal Tumors (1997) (8)
- PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses (2016) (8)
- Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. (2017) (8)
- Imaging in Lymphoma: The Key Role of Fluorodeoxyglucose-Positron Emission Tomography. (2015) (8)
- Evaluation of focal liver lesions: fast-recovery fast spin echo T2-weighted MR imaging. (2006) (8)
- The role of multimodal imaging in guiding resectability and cytoreduction in pancreatic neuroendocrine tumors: focus on PET and MRI (2019) (7)
- The Prostate Cancer Clinical Trials Consortium (PCCTC) bone scan data capture tool for clinical trials using Prostate Cancer Working Group 2 (PCWG2) criteria: Effect on data accuracy and workload. (2011) (7)
- A phase II study of talazoparib (BMN 673) in patients with homologous recombination repair deficiency (HRRD) positive stage IV squamous cell lung cancer (Lung-MAP Sub-Study, S1400G). (2019) (7)
- Current and Future Role of Medical Imaging in Guiding the Management of Patients With Relapsed and Refractory Non-Hodgkin Lymphoma Treated With CAR T-Cell Therapy (2021) (7)
- FLT-PET At 6 Weeks Predicts Response Assessed by CT at 12 Weeks in Melanoma Patients Treated With Pembrolizumab. (2020) (7)
- Response phenotype as a predictive biomarker to guide treatment with targeted therapies. (2013) (7)
- Multi-site, multi-platform comparison of MRI T1 measurement using the system phantom (2021) (7)
- Phase II trial of pegylated interferon-alpha 2b in patients with advanced renal cell carcinoma. (2008) (7)
- Oncology clinical trials (2013) (7)
- Effect of CT image acquisition parameters on diagnostic performance of radiomics in predicting malignancy of pulmonary nodules of different sizes (2021) (7)
- Biomarker analysis and final results of INT70/09 phase II proof-of-concept study of pazopanib (PZP) in refractory urothelial cancer (UC). (2012) (6)
- Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer (2005) (6)
- Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G. (2021) (6)
- Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation (2020) (6)
- Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753). (2019) (6)
- Distinguishing benign and malignant lesions on contrast-enhanced breast cone-beam CT with deep learning neural architecture search. (2021) (6)
- Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. (2019) (6)
- A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma (2004) (6)
- Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in BRAFV600E-Mutated Metastatic Melanoma Patients Treated with Vemurafenib (2015) (6)
- Predicting death or recurrence of portal hypertension symptoms after TIPS procedures (2022) (5)
- Prognostic significance of adrenal gland morphology at CT in patients with three common malignancies. (2012) (5)
- Assessing immune response upon systemic RNA vaccination on [18F]-FDG PET/CT for COVID-19 vaccine and then for immuno-oncology? (2021) (5)
- Interim FDG PET Imaging in CALGB 50203 Trial of Stage I/II Non-Bulky Hodgkin Lymphoma: Would Using Combined PET and CT Criteria Better Predict Response Than Each Test Alone?, (2011) (5)
- Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapy (2022) (5)
- Automated segmentation of mesothelioma volume on CT scan (2005) (5)
- 81 Development of a computer method for volumetric response assessment in mesothelioma (2006) (5)
- A birdcage resonator for intracavitary MR imaging. (1993) (5)
- Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases. (2004) (5)
- Phase II Study of a Non‐Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas (2016) (5)
- Advances in magnetic resonance imaging: applications in body imaging. (1998) (5)
- Review and interpretation of MR imaging studies with PACS: creating uniform series descriptors for radiologists and referring physicians. (2002) (4)
- Artificial Intelligence and Early Detection of Pancreatic Cancer (2021) (4)
- MR imaging after surgery for musculoskeletal neoplasm. (2002) (4)
- Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions (2021) (4)
- Corrigendum: Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC (2017) (4)
- Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning (2021) (4)
- Don't overlook spleen glucose metabolism on [18F]-FDG PET/CT for cancer drug discovery and development. (2021) (4)
- Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response. (2006) (4)
- Randomized phase II study of hepatic arterial embolization of hepatocellular carcinoma (HCC) with micospheres alone (bead block (BB)) versus doxorubicin loaded microspheres (LC bead (LCB)) (2014) (4)
- Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas (2017) (4)
- Nonenhancing Component of Clear Cell Renal Cell Carcinoma on Computed Tomography Correlates With Tumor Necrosis and Stage and Serves as a Size-Independent Prognostic Biomarker. (2019) (4)
- MR/ultrasound fusion-guided biopsy in prostate cancer: what is the evidentiary standard? (2015) (4)
- Advances in cross-sectional imaging of colorectal cancer. (1999) (4)
- Early clinical and toxicological results of a combi nation of natural glycolysis inhibitors (METABLOC™) on cancer patients. (2012) (4)
- 318 Effects of Radiologic Tumor Response of Anti-Glypican-3 GC33 and Multi Tyrosine Kinases Inhibitor Sorafenib in Hepatocellular Carcinoma (2012) (3)
- Assessing changes in tumor size with CT scans in lung cancer: are volumetric measurements better than unidimensional (1D) and bidimensional (2D) assessments? (2008) (3)
- CASE REPORT Endometrial Stromal Sarcoma: Objective Response to Letrozole (2001) (3)
- Identifying Robust Radiomics Features for Lung Cancer by Using In-Vivo and Phantom Lung Lesions. (2021) (3)
- Hepatic arterial infusion (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response (2005) (3)
- Imaging and prostate cancer (1996) (3)
- An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans (2021) (3)
- CT radiomic analysis using lymph-node-density profile in correlation to SUV-value for PET/CT based N-Staging (2016) (3)
- Advances in imaging. (1994) (3)
- Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al. (2015) (3)
- Composite assessment of treatment response in patients (pts) with locally advanced basal cell carcinoma (laBCC): Sonidegib efficacy using two sets of response criteria. (2015) (3)
- Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170). (2014) (3)
- High serum LDH and liver metastases are the dominant predictors of primary cancer resistance to anti-PD(L)1 immunotherapy. (2022) (3)
- Role of radiomics to differentiate benign from malignant pheochromocytomas and paragangliomas on contrast enhanced CT scans. (2019) (3)
- Feasibility of Using Limited-Population-Based Average R 10 for Pharmacokinetic Modeling of Osteosarcoma Dynamic Contrast-Enhanced MRI Data (2009) (2)
- Radiomic signatures for identification of tumors sensitive to nivolumab or docetaxel in squamous non-small cell lung cancer (sqNSCLC) (2019) (2)
- The Importance of Imaging in Radiation Oncology for National Clinical Trials Network Protocols. (2018) (2)
- A machine-learning-based combination of criteria to detect bladder cancer lymph node metastasis on [18F]FDG PET/CT: a pathology-controlled study (2022) (2)
- Monitoring Responses to Therapy in Oncology (2014) (2)
- Chapter 17 – Magnetic resonance imaging of the liver, biliary tract, and pancreas (2012) (2)
- Potential Theranostic Role of Bone Marrow Glucose Metabolism on Baseline 18F-FDG PET/CT in Metastatic Melanoma (2021) (2)
- Novel methodology of response assessment in hepatocellular carcinoma (HCC) -Assessing response by change in tumor enhancement in distinction from conventional means. (2004) (2)
- Evaluation of number of target lesions to analyze in time to progression by RECIST (2007) (2)
- Development of a Queriable Database for Oncology Outcome Analysis (2008) (2)
- Letter to the Editor re: Perfusion MRI for the prediction of treatment response after preoperative chemoradiotherapy in locally advanced rectal cancer (2013) (2)
- A Web-Based Response-Assessment System for Development and Validation of Imaging Biomarkers in Oncology (2019) (2)
- Clinical Trial Design and Development Work Group Within the Quantitative Imaging Network (2020) (2)
- Baseline radiomic signature to estimate overall survival in patients with non-small cell lung cancer. (2023) (2)
- Correlating surrogate endpoints with overall survival at the individual patient level in BRAF-mutated metastatic melanoma patients treated with vemurafenib. (2015) (2)
- Chapter 2 – Surgical and radiologic anatomy of the liver, biliary tract, and pancreas (2017) (2)
- Adenocarcinoma of the distal esophagus and gastroesophageal junction (1989) (2)
- Measuring tumor burden: comparison of automatic and manual techniques (2004) (2)
- Measuring hepatic metastases to colon cancer. (2006) (1)
- Treatment outcome and survival for patients (pts) with sarcomatoid-variant metastatic renal cell carcinoma (RCC): Memorial Sloan-Kettering Cancer Center (MSKCC) experience. (2009) (1)
- Response to neoadjuvant chemotherapy as measured by PET predicts outcome after liver resection for colorectal metastases. (2006) (1)
- Quantitative imaging using CT (2019) (1)
- 3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria (2015) (1)
- Diagnosis and treatment of focal nodular hyperplasia (1996) (1)
- The who and what of imaging in sarcoma and correlation with survival. (2015) (1)
- Dynamic contrast enhanced MRI (DCE-MRI) to measure antiangiogenic therapy and predict treatment response in primary liver cancer (PLC). (2010) (1)
- Radiology pathology conference. A 67-year-old man with a 1-week history of right upper quadrant pain radiating to the back. (1989) (1)
- Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC). (2020) (1)
- A comparative assessment of the incidence of steatohepatitis seen with modern chemotherapy agents (2005) (1)
- Alliance/CALGB 80802: Impact of hepatitis C (HCV) on doxorubicin (DO) + sorafenib (S) versus S in patients (pts) with advanced hepatocellular carcinoma (aHCC). (2021) (1)
- Outcomes of melanoma brain metastases treated with stereotactic radiosurgery with and without concurrent immune checkpoint therapy. (2017) (1)
- Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non???squamous NSCLC: P3-097 (2007) (1)
- Reply to G. Keramida et al. (2015) (1)
- The Role of Novel Imaging Techniques in Clinical Trials (2018) (1)
- 819 Radiomic markers associated with clinical benefit in advanced uveal melanoma patients with radiographic progression on tebentafusp (2021) (1)
- Pharmaco-kinetics/dynamics (PK/PD) evaluation and individual patient cross-over studies with growth trajectory assessment to adaptively develop ilorasertib. (2017) (1)
- Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2014) (1)
- Utility of an Informational Intranetin a Radiology Department (2003) (1)
- QIN. Promise and pitfalls of quantitative imaging in oncology clinical trials (2012) (1)
- Fluorodeoxyglucose Positron EmissionTomography as an Outcome Measure for CastrateMetastatic Prostate CancerTreatedwith Antimicrotubule Chemotherapy (2005) (1)
- Characterization of Renal Masses with Diffusion-Weighted MR Imaging-- A Preliminary Experience (2007) (1)
- Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. (2023) (1)
- Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results? (2011) (1)
- Correlation of survival outcomes with progression heterogeneity in patients (pts) treated with pembrolizumab (pembro). (2018) (1)
- The Impact of Image Acquisition Parameters and ComBat Harmonization on the Predictive Performance of Radiomics: A Renal Cell Carcinoma Model (2022) (1)
- Comparing single-shot RARE and multislice HASTE sequences. (1999) (1)
- POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC). (2020) (1)
- The NCCN Kidney Cancer Clinical Practice Guidelines in OncologyTM (2009) (1)
- P3-097: Regressions 14 days following bevacizumab as a single agent as part of neoadjuvant chemotherapy for resectable non–squamous NSCLC (2007) (1)
- Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. (2022) (1)
- Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (2015) (1)
- Variability of pelvic MRI performance in a prospective multicenter rectal cancer trial NCCTG N1048 (Alliance). (2018) (1)
- CONTRAST-ENHANCED ULTRASOUND MONITORING OF PERFUSION CHANGES IN HEPATIC NEUROENDOCRINE METASTASES AFTER SYSTEMIC VERSUS SELECTIVE ARTERIAL (2013) (1)
- Impact of normal tissue uptake using 68 Ga DOTATOC-PET/CT in patients with neuroendorcine tumor - a follow-up study (2012) (1)
- Reply to E.M. Gilles (2012) (1)
- Colorectal Cancer Imaging (2007) (1)
- Reproducibility of computed tomography (CT) measurements of lung cancer (2008) (1)
- Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer (2005) (1)
- Toward radiomics for assessment of response to systemic therapies in lung cancer (2020) (1)
- Imaging in oncology: From unknown primary to therapy response assessment (2002) (0)
- Is local review of positron emission tomography scans sufficient in diffuse large B‐cell lymphoma clinical trials? A CALGB 50303 analysis (2023) (0)
- Phase I Evaluation ofJ 591 as a Vascular Targeting Agent in Progressive SolidTumors (2007) (0)
- Using virtual clinical trials to determine the accuracy of AI-based quantitative imaging biomarkers in oncology trials using standard-of-care CT (2022) (0)
- Magnetic resonance imaging of the bone marrow (MRBM) as an outcome measure for patients with metastatic prostate cancer. (2006) (0)
- CirculatingTumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer (2007) (0)
- Early response metrics for predicting trial outcomes: A report from volumetric CT for precision analysis of clinical trials (Vol-PACT). (2018) (0)
- MO‐C‐AUD‐01: The Emerging Role of Imaging as a Biomarker for Response (2007) (0)
- ProspectiveAssessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by theAddition of Everolimus (2007) (0)
- Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer 1 (2003) (0)
- 410 Diagnostic imaging in oncology: New challenges and changing strategies (1996) (0)
- Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202. (2021) (0)
- Paclitaxel, E stramustine P hosphate, a nd C arboplatin i n Patients W ith A dvanced P rostate C ancer (2006) (0)
- A Machine-learning Signature Performs as Well as Experts' Consensus to Diagnose Pelvic Lymph Node Involvement in Bladder Cancer on [18F]-FDG PET/CT: A Pathology-controlled Study (2021) (0)
- Semi-automated validation of centralized independent review of radiological data in the OPUS trial. (2014) (0)
- The PCCTC imaging data capture toolset: An analysis of its impact on prostate cancer clinical trial accuracy and workload. (2011) (0)
- SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study). (2020) (0)
- Response assessment parameters in esophageal cancer - conventional and novel techniques. (2004) (0)
- Improving outcome of liver resection in patients with colorectal metastases (2008) (0)
- Correction to: A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma (2020) (0)
- Circulating tumor cells as prognostic biomarkers in patients with metastatic prostate cancer (2007) (0)
- Quantitative Osteosarcoma DCE-MRI : How Long is the Acquisition Time Necessary ? (2009) (0)
- Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance] (2020) (0)
- ponse Evaluation to Aid Biomarker Development (2010) (0)
- Abstract No. 354 EE: Standardized Advanced Imaging for Tumor Response Assessment in Clinical Trials for Image Guided Interventions (2008) (0)
- of Patient-Derived Tumor Xenografts Involving Triple-Negative Breast Cancer (2020) (0)
- Utility of an informational intranet in a radiology department. (2003) (0)
- Intracavitary birdcage resonator: Applications to the human prostate (1995) (0)
- 132 A phase I and pharmacokinetic clinical trial of subcutaneous (sc) VEGF trap in advanced solid tumor patients (2004) (0)
- P2.11-30 Effects of the Size of Nodules, Reconstruction Slice Thickness and Convolution Kernel on Radiomics Model in Classifying Pulmonary Nodules (2019) (0)
- Abstract PO022: Multidimensional longitudinal assessment of patients under treatment for advanced endometrial cancer: a new tool to advance research on human disease (2021) (0)
- 1019 Liver Atrophy and Regeneration in Non-Cirrhotic Portal Vein Thrombosis: Effect of Surgical Shunts (2012) (0)
- Association of early tumor growth rate and survival outcomes in first-line metastatic non–small cell lung cancer (mNSCLC). (2022) (0)
- Quantitative Volume and Density Response Assessment: Sarcoma and HCC as a Model (2014) (0)
- Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis (2022) (0)
- Tumor contrast retention immediately following embolization predicts subsequent radiologic tumor necrosis after bland and drug eluting bead embolotherapy of HCC (2013) (0)
- Imaging the liver: Selected topics (2002) (0)
- CT Slice Thickness and Convolution Kernel Affect Performance of a Radiomic Model for Predicting EGFR Status in Non-Small Cell Lung Cancer: A Preliminary Study (2018) (0)
- Cross-sectional imaging for HPB disorders (MRI and CT) (2010) (0)
- Solid Tumor Response Criteria (2021) (0)
- Erratum to: Bland and tumor thrombi in abdominal malignancies: magnetic resonance imaging assessment in a large oncologic patient population (2010) (0)
- Abstract 3832: Tolerance of oral lipoid acid and hydroxycitrate combination in cancer patients: first approach of the cancer metabolism research group (2012) (0)
- The EGF Receptor (EGFR) Continues to Be a Promising Target in NSCLC (2014) (0)
- PCK3145, a novel multitargeted signalling agent for the treatment of castrate metastatic prostate cancer (CMPC) (2007) (0)
- Quantitative contrast peritoneography for intraperitoneal chemotherapy. (2012) (0)
- Reply to A. Braillon, M. Boulin et al, and J.-H. Zhong et al. (2017) (0)
- review Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence (2010) (0)
- The potential in artificial intelligence-driven radiomic signature to predict survival in patients with metastatic colorectal cancer treated with cetuximab-based therapy. (2020) (0)
- SU‐E‐CAMPUS‐J‐02: Exploring Appropriate CT Acquisition Parameters for Measuring Tumor Volumes in Response Assessment Using An Anthropomorphic Thorax Phantom (2013) (0)
- Novel biomarkers in NSCLC: Radiomic analysis, kinetic analysis, and circulating tumor DNA. (2022) (0)
- Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary (2016) (0)
- Qualification of FDG PET/CT as an oncologic biomarker: A methodology demonstration for lymphoma (2012) (0)
- Real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes (PROs) in a phase II clinical trial. (2012) (0)
- Umbrella Test the effect of one or more drugs on one or more single mutations in a variety of cancer types Test the impact of different drugs on different mutations in a single type of cancer Basket (2015) (0)
- A phase II study for prostate cancer monitoring using 18F-DCFPyL and blood-based biomarkers. (2019) (0)
- Metrics for measuring tumor burden: A comparison of unidimensional and volumetric measurements. (2011) (0)
- Relationship of variability in tumor measurement and response assessment. (2012) (0)
- Medical imaging and its use in clinical trials (2005) (0)
- Phase I Clinical Trial of Histone Deacetylase Inhibitor : Suberoylanilide Hydroxamic Acid Administered Intravenously 1 (2003) (0)
- Book reviewMR Imaging of the Body, E.J. Rummeny, P. Reimer, W. Heindel (Eds.), Thieme, New York/Stuttgart (2009), p. 690, 1350 illustrations, $USA199.95, ISBN: 978-3-13135-841-7 (2010) (0)
- Abstract 5451: Longitudinal proteomic assessment of patient with metastatic apocrine adenocarcinoma reveals evolutionary selection for androgen-receptor-dependence and therapeutic response (2020) (0)
- Quality Assurance of Clinical Trials in the Management of Cancer in the Head and Neck (2011) (0)
- Retrospective analysis of standard-of-care imaging in patients with cutaneous T-cell lymphoma (2021) (0)
- Assessment of response to treatment (2009) (0)
- Response criteria for intratumoral immunotherapy in solid tumors: ItRECIST. (2020) (0)
- Minor response rate to predict patient survival. (2013) (0)
- Magnetic Resonance Imaging of the Liver, Pancreas, and Biliary Tract (2007) (0)
- P2.12-03 External Validation of a Novel CT-Based Prognostic Radiomic Signature in Patients with Metastatic NSCLC in SWOG S0819 Phase III Randomized Trial (2022) (0)
- Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib +/- doxorubicin: Correlative science from CALGB 80802 (Alliance). (2021) (0)
- SU‐E‐T‐40: Exploring the Reproducibility of Tumor Volumes Measured by Radiologist, Computer‐Aided Radiologist and Computer Alone (2011) (0)
- Variability in response definition and confirmation practices in randomized phase II and III trials in colorectal cancer. (2004) (0)
- Variability in response definition and confirmation practices in randomized phase II and III trials in colorectal cancer (2004) (0)
- Convolutional Neural Network Addresses the Confounding Impact of CT Reconstruction Kernels on Radiomics Studies (2021) (0)
- 586 Response assessment classification: effect of multiple measurement criteria and parameters (2004) (0)
- On the design, conduct and lessons learned from Lung-MAP (SWOGS1400): A biomarker-driven master protocol to evaluate biomarker-driventherapies for previously-treated squamous lung cancer (2021) (0)
- TU-A-12A-07: CT-Based Biomarkers to Characterize Lung Lesion: Effects of CT Dose, Slice Thickness and Reconstruction Algorithm Based Upon a Phantom Study. (2014) (0)
- Evaluation o f T umor M easurements i n O ncology: U se o f Film-Based a nd E lectronic T echniques (2000) (0)
- Prospective evaluation of 18F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases (2021) (0)
- Estimating the accuracy and precision of quantitative imaging biomarkers as endpoints for clinical trials using standard-of-care CT (2022) (0)
- Comparing true tumor volume to unidimensional and bidimensional measurements in lung cancer-A better discriminator of response? (2006) (0)
- Intraperitoneal Chemotherapy For The Treatment Of Malignant Peritoneal Mesothelioma (2015) (0)
- Diffusion-weighted MRI and (68)Ga-DOTATOC PET for early monitoring of response to loco-regional (90)Y-/(177)Lu-DOTATOC therapy in patients with neuroendocrine liver metastases (2012) (0)
- Prostate Cancer: Systemic therapy (2008) (0)
- Book reviewAbdominal–pelvic MRI, 2nd ed, R.C. Semelka (Ed.), Wiley, Hoboken (NJ) (2006), [1427 pages, 1500 illustrations, US$295.00], ISBN: 0471692735 (2006) (0)
- Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials. (2013) (0)
- Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results. (2008) (0)
- Cystic Neoplasms of the Pancreas: Diagnosis and imaging (2009) (0)
- Computers in Radiology (2002) (0)
- A Multi-Institutional Biomarker Study of Large B-cell Lymphomas in FDG PET/CT - Experiences within the Oncology Biomarker Qualification Initiative (OBQI) (2016) (0)
- Progression-Free Survival The Imaging Viewpoint: How Imaging Affects Determination of (2013) (0)
- Oncogene Inactivation Survival and Death Signals Can Predict Tumor Response to Therapy After (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Lawrence Howard Schwartz?
Lawrence Howard Schwartz is affiliated with the following schools: